業績
2023
Wada H, Hikiami R, Kusui M, Minamiyama S, Asada-Utsugi M, Shodai A, Muramatsu S, Morimura T, Urushitani M. In vivo analysis of aggregation propensity of low levels of mislocalized TDP-43 on cytopathological and behavioral phenotype of ALS/FTLD. Neurosci Res. 193: 41-51, 2023.
Minamiyama S, Sakai M, Yamaguchi Y, Kusui M, Wada H, Hikiami R, Tamaki Y, Asada-Utsugi M, Shodai A, Makino A, Fujiwara N, Ayaki T, Maki T, Warita H, Aoki M, Tomonaga K, Takahashi R* and Urushitani M*. Efficacy of oligodendrocyte precursor cells as delivery vehicles for single-chain variable fragment to misfolded SOD1 in ALS rat model. Mol Ther Methods Clin Dev. 28: 312-329, 2023.
2022
Tamaki Y, Urushitani M. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD. Int J Mol Sci. 2022.
Hikiami, R., Morimura, T., Ayaki, T., Tsukiyama, T., Morimura, N., Kusui, M., Wada, H., Minamiyama, S., Shodai, A., Asada-Utsugi, M., Muramatsu, S. I., Ueki, T., Takahashi, R., & Urushitani, M. Conformational change of RNA-helicase DHX30 by ALS/FTD-linked FUS induces mitochondrial dysfunction and cytosolic aggregates. Sci Rep 2022.
Asada-Utsugi, M., Uemura, K., Ayaki, T., M, T. U., Minamiyama, S., Hikiami, R., Morimura, T., Shodai, A., Ueki, T., Takahashi, R., Kinoshita, A., & Urushitani, M. Failure of DNA double-strand break repair by tau mediates Alzheimer’s disease pathology in vitro. Commun Biol. 2022.
Sawamura M, Imamura K, Hikawa R, Enami T, Nagahashi A, Yamakado H, Ichijyo H, Fujisawa T, Yamashita H, Minamiyama S, Kaido M, Wada H, Urushitani M, Inoue H, Egawa N, Takahashi R. Cellular analysis of SOD1 protein-aggregation propensity and toxicity – A case of ALS with slow progression harboring homozygous SOD1-D92G mutation. Sci Rep 2022.
Kobashi S, Terashima T, Katagi M, Urushitani M, Kojima H. Bone marrow-derived inducible microglia-like cells ameliorate motor function and survival in a mouse model of amyotrophic lateral sclerosis. Cytotherapy. 2022.
2021
Tanaka N, Kimura S, Kamatari Y, Nakata K, Kobatake Y, Inden M, Yamato O, Urushitani M, Maeda S, Kamishina H. In vitro evidence of propagation of superoxide dismutase-1 protein aggregation in canine degenerative myelopathy. Vet J. 2021.
Nakata K, Namiki M, Nishida H, Sakai H, Yamato O, Urushitani M, Maeda S, Kamishina H. Up-regulated spinal microRNAs induce aggregation of superoxide dismutase 1 protein in canine degenerative myelopathy. Res Vet Sci. 2021.
2020
Kobashi S, Terashima T, Katagi M, Nakae Y, Okano J, Suzuki Y, Urushitani M, Kojima H. Transplantation of M2-deviated microglia promotes recovery of motor function after spinal cord injury in mice. Mol Ther. 2020.
2019
Zong C, Hasegawa R, Urushitani M, Zhang L, Nagashima D, Sakurai T, Ichihara S, Ohsako S, Ichihara G. Role of microglial activation and neuroinflammation in neurotoxicity of acrylamide in vivo and in vitro. Arch Toxicol. 2019.
2018
Tamaki, Y., Shodai, A., Morimura, T., Hikiami, R., Minamiyama, S., Ayaki, T., Tooyama, I., Furukawa, Y., Takahashi, R., & Urushitani, M. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci Rep. 2018.
2016
Uchida, T., Tamaki, Y., Ayaki, T., Shodai, A., Kaji, S., Morimura, T., Banno, Y., Nishitsuji, K., Sakashita, N., Maki, T., Yamashita, H., Ito, H., Takahashi, R., & Urushitani, M. CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS. Sci Rep. 2016.
2013
Shodai, A., Morimura, T., Ido, A., Uchida, T., Ayaki, T., Takahashi, R., Kitazawa, S., Suzuki, S., Shirouzu, M., Kigawa, T., Muto, Y., Yokoyama, S., Takahashi, R., Kitahara, R., Ito, H., Fujiwara, N., & Urushitani, M. Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43). Journal of Biological Chemistry. 2013.
2012
Shodai, A., Ido, A., Fujiwara, N., Ayaki, T., Morimura, T., Oono, M., Uchida, T., Takahashi, R., Ito, H., & Urushitani, M. Conserved acidic amino acid residues in a second RNA recognition motif regulate assembly and function of TDP-43. PloS One. 2012.
日本語総説
2023
引網亮太／漆谷 真
TDP-43の凝集体形成機序と治療戦略、いま新薬で加速する神経変性疾患研究（小野賢二郎編）
実験医学、羊土社、41(12)、1926-1932、2023
漆谷 真
ワクチン・抗体療法～開発中の治療～「ALS－どこまで分かり、どこまで治るか」
Clinical Neuroscience 41 (3) 417-419. 2023
2022
漆谷 真
神経変性疾患における抗体・ワクチン治療の開発現状と将来展望
実験医学 40 (20) 3371-3376, 2022
引網亮太／漆谷 真
異常蛋白質（TDP-43、C9orf72）と病態
脳神経内科．97巻2号, 108, 科学評論社, 2022
漆谷 真
ALSに対する創薬ストラテジーと開発現状.
Medical Science Digest. 48巻5号, 219, ニューサイエンス社, 2022
漆谷 真
筋萎縮性側索硬化症（ALS）に対する遺伝子治療
特集：神経疾患における遺伝医療の進歩
日本内科学会雑誌 第111巻第8号, 1527, 2022
2021
漆谷 真
ALSに対する抗体療法開発の現状
実験医学 39, 186, 2021
漆谷 真
ALSに対する抗体療法開発の現状
実験医学 39, 186, 2021
2020
引網亮太／南山素三雄／漆谷 真
筋萎縮性側索硬化症 – プロテイノパチーの観点から
医学のあゆみ. 273(1): 44-49, 2020
漆谷 真
筋萎縮性側索硬化症
特集 難病研究の進歩
生体の科学．71（ 5 ）：2─4，2020
2019
漆谷 真／玉木 良高／引網 亮太／南山 素三雄
ALSにおける免疫療法開発の現状と展望
特集「ALS2019」
BRAIN and NERVE. 71 (11): 1289-1301, 2019.